Brinker Capital Inc. boosted its holdings in EXACT Sciences Co. (NASDAQ:EXAS) by 4.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,693 shares of the medical research company’s stock after purchasing an additional 497 shares during the quarter. Brinker Capital Inc.’s holdings in EXACT Sciences were worth $1,099,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the business. First Hawaiian Bank boosted its position in shares of EXACT Sciences by 160.0% during the 1st quarter. First Hawaiian Bank now owns 325 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 200 shares during the last quarter. Shine Investment Advisory Services Inc. raised its holdings in EXACT Sciences by 130.2% during the 1st quarter. Shine Investment Advisory Services Inc. now owns 442 shares of the medical research company’s stock valued at $38,000 after buying an additional 250 shares during the period. Karp Capital Management Corp purchased a new stake in EXACT Sciences during the 4th quarter valued at $38,000. CWM LLC raised its holdings in EXACT Sciences by 777.1% during the 4th quarter. CWM LLC now owns 614 shares of the medical research company’s stock valued at $39,000 after buying an additional 544 shares during the period. Finally, Hanson McClain Inc. raised its holdings in EXACT Sciences by 377.5% during the 4th quarter. Hanson McClain Inc. now owns 955 shares of the medical research company’s stock valued at $60,000 after buying an additional 755 shares during the period. Institutional investors and hedge funds own 87.63% of the company’s stock.
EXAS stock traded down $2.04 during trading on Wednesday, reaching $94.91. 878,639 shares of the company traded hands, compared to its average volume of 1,810,490. EXACT Sciences Co. has a 12 month low of $47.78 and a 12 month high of $105.28. The company has a market cap of $12.48 billion, a P/E ratio of -69.79 and a beta of 1.84. The company has a debt-to-equity ratio of 1.02, a current ratio of 8.39 and a quick ratio of 8.13.
EXACT Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Tuesday, April 30th. The medical research company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.01). The business had revenue of $162.00 million during the quarter, compared to analyst estimates of $153.07 million. EXACT Sciences had a negative return on equity of 28.83% and a negative net margin of 41.58%. EXACT Sciences’s revenue was up 79.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.33) EPS. On average, analysts anticipate that EXACT Sciences Co. will post -2.13 EPS for the current year.
A number of analysts have weighed in on EXAS shares. Zacks Investment Research lowered EXACT Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, February 13th. UBS Group increased their target price on EXACT Sciences from $109.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, April 16th. Robert W. Baird increased their target price on EXACT Sciences from $90.00 to $102.00 and gave the stock an “outperform” rating in a research note on Thursday, February 21st. BTIG Research raised their price target on EXACT Sciences to $110.00 and gave the company a “positive” rating in a research note on Friday, February 22nd. Finally, Goldman Sachs Group upgraded EXACT Sciences from a “neutral” rating to a “buy” rating and raised their price target for the company from $85.00 to $120.00 in a research note on Tuesday, February 26th. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $108.45.
In other news, CFO Jeffrey Thomas Elliott sold 2,447 shares of the firm’s stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $93.20, for a total value of $228,060.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Katherine S. Zanotti sold 25,000 shares of the firm’s stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $92.81, for a total value of $2,320,250.00. Following the completion of the transaction, the director now owns 94,274 shares of the company’s stock, valued at $8,749,569.94. The disclosure for this sale can be found here. In the last three months, insiders sold 60,201 shares of company stock valued at $5,543,493. Corporate insiders own 3.20% of the company’s stock.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Recommended Story: How Do Front-End Loads Impact an Investment?
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.